A group of thirty-six doctors who specialize in Duchenne muscular dystrophy sent a letter to the Food and Drug Administration that urged approval of Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) experimental treatment eteplirsen. Shares of the biopharmaceutical leaped $3.61 to $21.61.
Doctors support eteplirsen approval
March 21, 2016 at 14:21 PM EDT
